ACHN News and Press, Achison Inc Cl A From 11/08/19

BioCryst (NASDAQ: BCRX ) has reported promising results from the phase 1 trial which is currently being carried out on BCX9930 to inhibit the alternative pathway of complement system. The trial is being carried out on 72 healthy volunteers and has resulted in a continuous suppression of mo...

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

Achillion Pharmaceuticals (NASDAQ: ACHN ): Q3 GAAP EPS of -$0.14 beats by $0.02 . Cash & equivalents of $229M. The company's acquisition by Alexion is expected to close by 1H20. Press Release More news on: Achillion Pharmaceuticals, Inc., Earnings news and commentary, Healthca...

– Reached an agreement to be acquired by Alexion;  transaction expected to close in first half of 2020 – – Danicopan (ACH-4471) received Breakthrough Therapy designation for treatment of PNH; Phase 2 combination trial top-line results to be presented at 61s...

BLUE BELL, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the acceptance of two abstracts...

NEW YORK, NY / ACCESSWIRE / November 5, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Cision Ltd (NYSE: CISN ) related to its ...

NEW YORK / ACCESSWIRE / November 1, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Innophos Holdings, Inc ( IPHS ) ("Innophos")...

Point Roberts, WA and Delta, BC - October 28, 2019 (Investorideas.com Newswire) Investorideas.com, a leading investor news resource covering pharmaceutical and biotech stocks releases a sector snapshot reporting on the growth of the global monoclonal antibody market and how this is affecting ind...

Alexion Pharmaceuticals ( ALXN ) announced that it would acquire Achillion Pharmaceuticals ( ACHN ) for approximately $930 million. There are other stipulations that were added to make this deal decent for Achillion. There are still some measures that must be closed before such a deal can ...

NEW YORK, NY / ACCESSWIRE / October 23, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Achillion Pharmaceuticals, Inc (NASDAQ: ACHN ...